Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Costs and economics

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Objectives The direct medical costs associated with Alzheimer's disease (AD) in the United States have been estimated to be over $360 billion USD, but this value does not reflect the substantial financial burden on unpaid caregivers and society. We estimated the economic burden of unpaid caregivers and patient productivity loss because of AD across all disease severity stages to better understand the indirect impacts of AD. Methods We performed a narrative literature review to identify estimates of unpaid caregiver burden and market productivity loss. In addition, we leveraged a published algorithm to estimate non-market productivity loss because of AD. Patient-level estimates were scaled to the population on the basis of AD prevalence in the United States (approximately 12.5 million), weighted by disease severity. Results The total annual indirect costs of unpaid caregiving and market and non-market productivity loss of AD increased with severity: $36 934 for mild cognitive impairment owing to AD, $65 565 for mild AD, $103 717 for moderate AD, and $145 250 for severe AD (2024 United States Dollars [USD]). Considering the current distribution of prevalent patients across severity stages, the total annual indirect cost was estimated at $832 billion, which includes $599 billion in unpaid caregiving costs and $233 billion in productivity losses. Conclusions Conventional cost estimates, which do not consider unpaid caregiver burden and patient productivity loss, significantly underestimate the total burden of AD. Both elements should be incorporated into cost estimates and value assessments to best capture the total indirect impact of AD and the value of new therapies.

What this study adds

Evidence grade: Early

This modelling study estimated total annual indirect costs of unpaid caregiving and market and non-market productivity loss in Alzheimer's disease at $832 billion, including $599 billion in unpaid caregiving costs and $233 billion in productivity losses. Reported effect size: Total annual indirect cost $832 billion (2024 USD); $36,934 to $145,250 per person by severity.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Fox, J., Mearns, E. S., Li, J., Rosettie, K. L., Majda, T., Lin, H., et al. (2025). Indirect Costs of Alzheimer's Disease: Unpaid Caregiver Burden and Patient Productivity Loss. Value in Health. https://doi.org/10.1016/j.jval.2024.10.3851

Vancouver

Fox J, Mearns ES, Li J, Rosettie KL, Majda T, Lin H, et al. Indirect Costs of Alzheimer's Disease: Unpaid Caregiver Burden and Patient Productivity Loss. Value in Health. 2025. doi:10.1016/j.jval.2024.10.3851. PMID: 39571734.

BibTeX

@article{fox2025-39571734,
  author  = {Fox, J. and Mearns, E. S. and Li, J. and Rosettie, K. L. and Majda, T. and Lin, H. and Kowal, S. L.},
  title   = {{Indirect Costs of Alzheimer's Disease: Unpaid Caregiver Burden and Patient Productivity Loss}},
  journal = {Value in Health},
  year    = {2025},
  doi     = {10.1016/j.jval.2024.10.3851},
  pmid    = {39571734},
  url     = {https://doi.org/10.1016/j.jval.2024.10.3851}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This modelling study estimated total annual indirect costs of unpaid caregiving and market and non-market productivity loss in Alzheimer's disease at $832 billion, including $599 billion in unpaid caregiving costs and $233 billion in productivity losses. It is about the economic burden of Alzheimer's disease and does not test any treatment, cure, or prevention.

Study details

How this study scored 50/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 3 of 12; Strength of evidence 2 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 2 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 3 of 5; Impact for its field and year 3 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record 1 of 4; Institution's track record 3 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 49 of the 98 points it could be judged on, which is 50 of 100. Total 50 of 100.49 of the 98 points we could judge = 50 of 100

Published in a peer-reviewed journal, and it is a computer model rather than new measurements. Scored zero for sample size, studied in people and randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 49 of the 98 points we could judge it on, which is 50 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Value in Health)
Journal's citation record 2 / 4 Value in Health: journal h-index 169 (OpenAlex, 2026-10-29)
Study design 3 / 12 A computer model rather than new measurements
Strength of evidence 2 / 5 Rated “early” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 25 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 8.3 citations a year over 3 year(s) since 2025
Impact for its field and year 3 / 6 Cited 6.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 2 / 4 Cited 25 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Stacey L. Kowal: h-index 11 (OpenAlex, whole career)
Institution's track record 3 / 3 University of Washington: institution h-index 3,540 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 39571734)
Free to read — / 2 Access not recorded — left out of this score
Points 49 / 98 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 49 of the 98 points we could judge it on is 50 out of 100.
Total 50 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Costs and economics from nearby years

Also in Costs and economics

21 studies in the library are filed under Costs and economics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Costs and economics hub.

Similar studies

More on Costs and economics

See all studies in Costs and economics →